| Literature DB >> 34153515 |
Claude Van Campenhout1, Ricardo De Mendonça1, Barbara Alexiou1, Sarah De Clercq1, Marie-Lucie Racu1, Claire Royer-Chardon1, Stefan Rusu1, Marie Van Eycken1, Maria Artesi2, Keith Durkin2, Patrick Mardulyn3, Vincent Bours4, Christine Decaestecker5, Myriam Remmelink1, Isabelle Salmon6, Nicky D'Haene7.
Abstract
Implementation of SARS-CoV-2 testing in the daily practice of pathology laboratories requires procedure adaptation to formalin-fixed and paraffin-embedded (FFPE) samples. So far, one study reported the feasibility of SARS-CoV-2 genome sequencing on FFPE tissues with only one contributory case out of two. The present study aimed to optimize SARS-CoV-2 genome sequencing using the Ion AmpliSeq SARS-CoV-2 Panel on 22 FFPE lung tissues from 16 deceased COVID-19 patients. SARS-CoV-2 was detected in all FFPE blocks using a real-time RT-qPCR targeting the E gene with Crossing Point (Cp) values ranging from 16.02 to 34.16. Sequencing was considered as contributory (i.e. with a uniformity >55%) for 17 FFPE blocks. Adapting the number of target amplification PCR cycles according to the RT-qPCR Cp values allowed to optimize the sequencing quality for the contributory blocks; i.e. 20 PCR cycles for blocks with a Cp value <28 and 25 PCR cycles for blocks with a Cp value between 28 and 30. The majority of blocks with a Cp value >30 were non-contributory. Comparison of matched frozen and FFPE tissues revealed discordance for only three FFPE blocks, all with a Cp value >28. Variant identification and clade classification was possible for 13 patients. The present study validates SARS-CoV-2 genome sequencing on FFPE blocks and opens the possibility to explore correlation between virus genotype and histopathological lesions.Entities:
Year: 2021 PMID: 34153515 PMCID: PMC8219372 DOI: 10.1016/j.jmoldx.2021.05.016
Source DB: PubMed Journal: J Mol Diagn ISSN: 1525-1578 Impact factor: 5.568
Figure 1Variation of mapped read numbers according to RT-qPCR crossing point (Cp) values and number of PCR cycles. Data are displayed as medians (circle, 20 PCR cycles; square, 25 PCR cycles; diamond, 30 PCR cycles), 25% to 75% quartiles (box plots), and nonoutliers (bars).
Figure 2Dot plot of SARS-CoV-2 genome uniformity against RT-qPCR crossing point (Cp) values. For the same block, three different library preparation protocols were tested by varying the number of target amplification PCR cycles. The different conditions are indicated as follows: circle, 20 PCR cycles; square, 25 PCR cycles; diamond, 30 PCR cycles. Spearman correlation between RT-qPCR Cp value and uniformity is −0.63 (P = 0.002) at 20 cycles, −0.86 (P < 10−6) at 25 cycles, and −0.81 (P = 0.000006) at 30 cycles.
Sequencing Metrics for Matched FFPE and Frozen Tissues
| Patient no. | RT-qPCR Cp value | Selected PCR cycles for target amplification | Sequencing quality for FFPE tissue | Sequencing quality for frozen tissue | Variants for FFPE tissue, | Variants for frozen tissue, | Variants with AF >90% for FFPE tissue, | Variants with AF >90% for frozen tissue, |
|---|---|---|---|---|---|---|---|---|
| 1 | 18.69 | 20 | Optimal | Optimal | 6 | 7 | 5 | 5 |
| 2-1 | 28.76 | 25 | Optimal | Optimal | 865 | 238 | 5 | 5 |
| 2-2 | 31.62 | / | NC | Optimal | / | 189 | / | 5 |
| 3 | 23.13 | 20 | Optimal | Optimal | 12 | 11 | 9 | 9 |
| 4 | 19.32 | 20 | Optimal | Optimal | 13 | 10 | 6 | 6 |
| 5-1 | 29.16 | 25 | Suboptimal | Suboptimal | 774 | 184 | 6 | 5 |
| 5-2 | 31.41 | / | NC | Suboptimal | / | 231 | / | 5 |
| 6 | 34.16 | / | NC | NC | / | / | / | / |
| 7 | 31.14 | 20 | Optimal | Optimal | 19 | 15 | 9 | 9 |
| 8-1 | 16.02 | 20 | Suboptimal | Poor | 8 | 10 | 7 | 7 |
| 8-2 | 21.57 | 20 | Optimal | Suboptimal | 9 | 7 | 7 | 7 |
| 9-1 | 27.96 | 20 | Poor | Suboptimal | 896 | 284 | 4 | 4 |
| 9-2 | 30.55 | 30 | Suboptimal | Optimal | 340 | 160 | 22 | 4 |
| 10 | 33.03 | / | NC | Suboptimal | / | 69 | / | 9 |
| 11-1 | 21.98 | 20 | Optimal | Optimal | 18 | 15 | 10 | 10 |
| 11-2 | 23.05 | 20 | Optimal | Optimal | 26 | 15 | 10 | 10 |
| 12-1 | 28.46 | 25 | Suboptimal | Suboptimal | 1025 | 293 | 6 | 7 |
| 12-2 | 29.69 | 25 | Suboptimal | Optimal | 589 | 210 | 9 | 7 |
| 13 | 20.59 | 20 | Optimal | Suboptimal | 15 | 9 | 7 | 7 |
| 14 | 30.88 | / | NC | Poor | / | 162 | / | 7 |
| 15 | 20.56 | 20 | Optimal | Optimal | 18 | 21 | 6 | 6 |
| 16 | 28.87 | 25 | Suboptimal | Poor | 707 | 314 | 8 | 5 |
AF, allelic frequency; Cp, crossing point; FFPE, formalin fixed, paraffin embedded; NC, non-contributory; /, not applicable.
Figure 3Variation of sequencing performances [number of mapped reads (A), uniformity (B), number of variants (C), and number of variants with an allelic frequency (AF) >0.9 (D)] obtained with the selected PCR condition, according to RT-qPCR crossing point (Cp) values for contributory blocks. Data are displayed as medians, 25% to 75% quartiles (box plots), and nonoutliers (bars). The U-test was applied. ∗P < 0.05, ∗∗P < 0.01.
Figure 4Partial sequence alignments of 21 formalin-fixed, paraffin-embedded blocks with three different numbers of target amplification cycles against the reference sequence NC_0455512.2. Key residue nucleotides for Global Initiative on Sharing All Influenza Data clade classification are indicated. Sequences for block 6 are not included in the alignment as they are much shorter than the others and do not align sufficiently well to the other sequences to give useful information.
Variant Frequencies
| Nucleotide variation | Gene | Mutation type | Amino acid change | Frequency |
|---|---|---|---|---|
| Upstream (5′UTR) | 13/13 | |||
| Missense | L149F | 1/13 | ||
| Missense | T265I/T85I | 1/12 | ||
| Synonymous | - | 1/13 | ||
| Synonymous | - | 13/13 | ||
| Missense | T1246I/T428I | 3/13 | ||
| Synonymous | - | 1/13 | ||
| Synonymous | - | 0/13 | ||
| Missense | G3278S/G15S | 3/13 | ||
| Missense | L3606F/L37F | 1/13 | ||
| Synonymous | - | 2/12 | ||
| Missense | P4715L/P323L | 13/13 | ||
| Synonymous | - | 6/12 | ||
| Synonymous | - | 1/13 | ||
| Missense | N5301S/N909S | 1/13 | ||
| Missense | S5809L/S485L | 1/13 | ||
| Synonymous | - | 0/13 | ||
| Synonymous | - | 1/13 | ||
| Synonymous | - | 1/13 | ||
| Missense | D614G | 13/13 | ||
| Synonymous | - | 2/12 | ||
| Missense | A1078S | 1/13 | ||
| Missense | Q57H | 2/12 | ||
| Missense | G251V | 0/13 | ||
| Missense | L84S | 0/13 | ||
| Missense | L139F | 1/13 | ||
| Synonymous | - | 1/13 | ||
| Missense | RG203KR | 4/13 | ||
| Missense | D340N | 1/12 |
UTR, untranslated region; -, no amino acid change.
Variant Profile per Patient
| Patient no. | Profile | GISAID clade | GISAID ID | Nextstrain clade | Pangolin COVID-19 classification |
|---|---|---|---|---|---|
| 1 | G | SARS-CoV-2/human/Brussels/1/2020_EPI_ISL_451935 | 20A | B.1 | |
| 2 | G | - | 20A | B.1 | |
| 3 | GH | SARS-CoV-2/human/Brussels/3/2020_EPI_ISL_452142 | 20A | B.1.9 | |
| 4 | G | SARS-CoV-2/human/Brussels/4/2020_EPI_ISL_452148 | 20A | B.1.83 | |
| 5 | G | - | 20A | B.1 | |
| 7 | GR | SARS-CoV-2/human/Brussels/7/2020_EPI_ISL_452140 | 20D | C11 | |
| 8 | GH | SARS-CoV-2/human/Brussels/8/2020_EPI_ISL_452149 | 20C | B.1.321 | |
| 9 | G | - | 20A | B.1.6 | |
| 11 | GR | SARS-CoV-2/human/Brussels/11/2020_EPI_ISL_452150 | 20D | B.1.1.1 | |
| 12 | GR | - | 20B | B.1.1 | |
| 13 | G | SARS-CoV-2/human/Brussels/13/2020_EPI_ISL_452151 | 20A | B.1 | |
| 15 | G | SARS-CoV-2/human/Brussels/15/2020_EPI_ISL_452152 | 20A | B.1 | |
| 16 | GR | - | 20D | C.11 |
COVID-19, coronavirus disease 2019; GISAID, Global Initiative on Sharing All Influenza Data; ID, identifier; -, viral sequences not deposited in GISAID.
GISAID (, last accessed May 7, 2021).
Figure 5Nextstrain classification for 13 patients.